Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal Shah, Roch Houot, Thibaut Leguay et al.|Journal of Hematology & Oncology|2022Cited by 78
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal Shah, Olalekan O. Oluwole, Ryan D. Cassaday et al.|Leukemia|2025Cited by 35
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal Shah, Armin Ghobadia, Ryan D. Cassaday et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 33